| OTC Markets: PROT
Proteonomix, Inc. is a biotechnology company, which is engaged in the discovery and development of stem cell therapeutics, tissue banking services and cosmeceutical products. The company is primarily focused on developing therapies and products based upon the use of human stem cells and their derivatives with an initial focus on diabetes and cardiac diseases. It has developed sufficient technology for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a unique cord blood banking cryopreservation bag and cosmetic products, utilizing a secreted matrix derived from stem cells. The company was formerly known as Azurel Ltd. and has changed its name to Proteonomix, Inc. in August 2008. Proteonomix was founded by Michael Moshe Cohen on June 26, 1995 and is headquartered in Hawthorne, NJ.